Actively Recruiting

Phase Not Applicable
Age: 25Years - 75Years
All Genders
NCT06415721

Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder

Led by VA Palo Alto Health Care System · Updated on 2025-08-13

40

Participants Needed

1

Research Sites

18 weeks

Total Duration

On this page

Sponsors

V

VA Palo Alto Health Care System

Lead Sponsor

S

Stanford University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Alcohol Use Disorders are currently positioned as the third leading cause of preventable death in the United States, constituting a humanitarian crisis with substantial financial burden on society and medical facilities. While several pharmacological interventions exist, 60% of individuals who seek these treatments relapse to alcohol within 6 months. These high relapse rates are due in part to elevated brain response to alcohol cues in the environment. This study seeks to evaluate the efficacy of one session of functional Magnetic Resonance Imaging (fMRI) guided transcranial magnetic stimulation (TMS) as a strategy to reduce brain reactivity to alcohol cues.

CONDITIONS

Official Title

Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder

Who Can Participate

Age: 25Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Between age 25 and 75.
  • Current DSM-5 diagnosis of moderate to severe Alcohol Use Disorder with 4 or more diagnostic symptoms.
  • Able to attend scheduled clinic visits.
  • Able to read, understand, and voluntarily sign informed consent before participating.
  • Stable medication regimen if on medications during the study.
  • Fluent in English.
Not Eligible

You will not qualify if you...

  • Contraindications to transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI) such as pacemaker, cochlear implant, deep brain stimulation, metal near the treatment area, claustrophobia, pregnancy, or breastfeeding.
  • Medical, neurological, or disease conditions interfering with participation or assessments.
  • Unable to safely stop medications that increase seizure risk at least two weeks before treatment.
  • Current substance abuse except caffeine or nicotine.
  • Presence of brain lesions, cerebral infarcts, active CNS diseases, alcohol-related seizures, or seizure disorders.
  • Recent suicide attempt within 30 days or current suicidal plan or intent.
  • Severe vision, hearing, or hand movement problems affecting study participation.
  • History of moderate to severe traumatic brain injury.
  • Taking benzodiazepines, neuroleptics, or medications altering seizure threshold.
  • Unstable chronic illness.
  • Current or lifetime bipolar disorder or psychosis.
  • Participation in another clinical trial involving interventions.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

VA Palo Alto Health Care System

Palo Alto, California, United States, 94304

Actively Recruiting

Loading map...

Research Team

D

Daniel McCalley

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here